Cinacalcet: A new treatment for secondary hyperparathyroidism in patients receiving hemodialysis

Pharmacotherapy

Volumn 25, Issue 5 I, 2005, Pages 709-716

  Byrnes, Cecelia A ^a   Shepler, Brian M ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Calcimimetic; Cinacalcet; Secondary hyperparathyroidism

Indexed keywords

AMITRIPTYLINE; CALCIMIMETIC AGENT; CALCIUM; CALCIUM CARBONATE; CINACALCET; KETOCONAZOLE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D; WARFARIN;

CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DYSPNEA; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM; TABLET; VOMITING;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; RENAL DIALYSIS;

EID: 18044398550     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.5.709.63595     Document Type: Review

References (22)

1. Johnson CA, McCarthy J, Bailie GR, Deane J, Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 2002;39:1270-7.
2. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;S73:14-19.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
4. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003;23:369-79.
5. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226-37.
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
7. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.
8. National Kidney Foundation. K/DOQ1 clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):S1-202.
9. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-9.
10. Amgen Inc. Sensipar (cinacalcet HCl) tablets product information. Thousand Oaks, CA; March 8, 2004.
11. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24.
12. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-54.
13. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83.
14. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
15. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004;308:627-35.
16. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant 2002;17:204-7.
17. Ohashi N, Uematsu T, Nagashima S, et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on hemodialysis both on the day of hemodialysis and on the day without hemodialysis. Br J Clin Pharmacol 2004;57:726-34.
18. Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004;44:1070-6.
19. Kumar GN, Sproul C, Poppe L, et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004;32:1491-500.
20. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-45.
21. Moe SM, Sprague SM, Cunningham J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl [abstr]. J Am Soc Nephrol 2003;14:463A-4.
22. Amgen Inc. Sensipar (cinacalcet HCl) tablets Web site, 2004. Available from www.sensipar.com. Accessed June 22, 2004.